Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer’s drug
WASHINGTON, Dec 29 (Reuters) - The U.S. Food and Drug Administration failed to adhere to its own guidance and internal practices during the approval process for Biogen's (BIIB.O) Alzheimer's drug Aduhelm, which was "rife with…